next generation therapeutics LLC

24 hemlock drive
great neck, new york 11024

NYS Entity Status
ACTIVE

NYS Filing Date
MAY 10, 2013

NYS DOS ID#
4401842

County
NASSAU

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - NEXT GENERATION THERAPEUTICS LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Sixgill®, LLC Launches Sense 2.0
    By Business Wire - Thursday Oct 12, 2017

    Sixgill, LLC, the leader in sensor data services for governing IoE, today unveiled the next generation of its universal and highly scalable sensor data services platform, Sixgill Sense 2.0. Sense 2.0 provides vital capabilities...

    Source: VentureBeat
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Inside Maine's Exclusive Prouts Neck Community
    Thursday Aug 10, 2017

    Many of the 200 or so homes on this the rocky peninsula have been in the same families for generations.

    Source: The Wall Street Journal: Lifestyle
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York